"Clinical-CT mismatch" and the response to systemic thrombolytic therapy in acute ischemic stroke

Stroke. 2005 Aug;36(8):1695-9. doi: 10.1161/01.STR.0000173397.31469.4b. Epub 2005 Jul 7.

Abstract

Background and purpose: Mismatch between clinical deficits and imaging lesions in acute stroke has been proposed as a method of identifying patients who have hypoperfused but still have viable brain, and may be especially apt to respond to reperfusion therapy. We explored this hypothesis using a combined database including 4 major clinical trials of intravenous (IV) thrombolytic therapy.

Methods: To determine what the radiological correlates of a "matched" functional deficit are, we calculated the relationship between the ASPECT score of the 24-hour (follow-up) CT scan and the 24-hour National Institutes of Health Stroke Scale (NIHSS) score on the subsample with ASPECT scores performed at this time (n=820). Based on this empirical relationship, we computed the absolute difference between the observed baseline ASPECT score and the "expected" score (ie, matched) based on baseline NIHSS for all patients (n=2131). We tested whether patients with better than expected baseline ASPECTS were more likely to benefit from IV recombinant tissue plasminogen activation (rtPA).

Results: At 24 hours, there was a strong, linear, negative correlation between NIHSS and ASPECTS (r2=0.33, P<0.0001); on average, an increase of 10 points on NIHSS corresponded to a decrease of approximately 3 points on ASPECTS. At baseline, the average degree of mismatch between the observed and "expected" ASPECTS was 2.1 points (interquartile range, 1.0 to 3.4). However, multiple analyses failed to reveal a consistent relationship between the degree of clinical-CT mismatch at baseline and a patient's likelihood of benefiting from IV rtPA.

Conclusions: Clinical-CT mismatch using ASPECT scoring does not reliably identify patients more or less likely to benefit from IV rtPA.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Brain / pathology
  • Brain Ischemia / pathology*
  • Humans
  • Infusions, Intravenous
  • Linear Models
  • Neurologic Examination / methods
  • Plasminogen Activators / therapeutic use
  • Probability
  • Recombinant Proteins / therapeutic use
  • Reperfusion
  • Severity of Illness Index
  • Stroke / therapy*
  • Thrombolytic Therapy / methods*
  • Time Factors
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome

Substances

  • Recombinant Proteins
  • Plasminogen Activators